INSP

$62.247.40%-4.975

Inspire Medical Systems Inc (INSP)

Date: O: H: L: C: Vol:

Inspire Medical Systems Inc stock is traded at $62.24, with a volume of 437,296. It is down -7.40% in the last 24 hours and down -11.05% over the past month. Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.

Previous Close:

$67.21

Open:

$65.04

24h Volume:

437,296

Relative Volume:

0.64

Market Cap:

$1.80B

Revenue:

$915.25M

Net Income/Loss:

$131.14M

P/E Ratio:

13.92

EPS:

$4.47

Net Cash Flow:

$96.71M

1W Performance:

-12.71%

1M Performance:

-11.05%

6M Performance:

+9.76%

1Y Performance:

-15.57%

1-Day Range:

$60.20$65.04

1-Week Range:

$65.80$71.99

52-Week Range:

$38.91$147.03

Inspire Medical Systems Inc Stock (INSP) Company Profile

Name

Inspire Medical Systems Inc

Sector

Healthcare

Industry

Medical Devices

Phone

763-957-5037

Address

5500 WAYZATA BLVD, GOLDEN VALLEY, USA

Employee

1,333

@inspiresleep

Next Earnings Date

null

Latest SEC Filings

SEC

INSP's Discussions on X

Market Cap

Revenue

Net Income

Cash Flow

EPS

Inspire Medical Systems Inc Stock (INSP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-26	Initiated	Barclays	Underweight
Aug-04-26	Upgrade	Oppenheimer	Perform → Outperform
Jul-28-26	Resumed	UBS	Sell
Jun-23-26	Downgrade	Evercore ISI	Outperform → In-line
May-22-26	Downgrade	BofA Securities	Neutral → Underperform
May-05-26	Downgrade	BofA Securities	Buy → Neutral
May-05-26	Downgrade	Piper Sandler	Overweight → Neutral
Feb-13-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Feb-12-26	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-12-26	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-27-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-22-26	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-26	Downgrade	Truist	Buy → Hold
Dec-08-25	Upgrade	Oppenheimer	Perform → Outperform
Dec-02-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-26-25	Upgrade	Truist	Hold → Buy
Nov-25-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Nov-24-25	Upgrade	Stifel	Hold → Buy
Nov-04-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-24-25	Downgrade	Jefferies	Buy → Hold
Sep-22-25	Downgrade	UBS	Buy → Neutral
Sep-02-25	Initiated	Evercore ISI	Outperform
Aug-05-25	Downgrade	JP Morgan	Overweight → Neutral
Aug-05-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Aug-05-25	Downgrade	Truist	Buy → Hold
Nov-20-24	Upgrade	BofA Securities	Neutral → Buy
May-08-24	Downgrade	BofA Securities	Buy → Neutral
Apr-19-24	Initiated	RBC Capital Mkts	Outperform
Mar-19-24	Initiated	Morgan Stanley	Overweight
Feb-06-24	Resumed	KeyBanc Capital Markets	Overweight
Jan-19-24	Initiated	Jefferies	Buy
Jan-02-24	Downgrade	Stifel	Buy → Hold
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jul-19-23	Initiated	Robert W. Baird	Outperform
Apr-14-23	Initiated	Mizuho	Buy
Mar-29-23	Initiated	UBS	Buy
Dec-13-22	Upgrade	Goldman	Neutral → Buy
Dec-13-22	Initiated	KeyBanc Capital Markets	Overweight
Apr-13-22	Initiated	Truist	Buy
Apr-06-22	Initiated	Wolfe Research	Peer Perform
Mar-02-22	Resumed	BofA Securities	Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Dec-15-20	Downgrade	Goldman	Buy → Neutral
Nov-03-20	Upgrade	BofA Securities	Neutral → Buy
Nov-03-20	Upgrade	Oppenheimer	Underperform → Perform
Sep-22-20	Initiated	JP Morgan	Overweight
Sep-02-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Downgrade	BofA Securities	Buy → Neutral
Jul-15-20	Initiated	Goldman	Buy
Jun-18-20	Reiterated	Piper Sandler	Overweight
May-18-20	Initiated	Lake Street	Buy
Apr-28-20	Upgrade	BofA/Merrill	Neutral → Buy
Apr-09-20	Initiated	Piper Sandler	Overweight
Jan-28-20	Initiated	Oppenheimer	Underperform
Jan-27-20	Initiated	Oppenheimer	Underperform
Nov-06-19	Upgrade	Berenberg	Sell → Hold
Feb-05-19	Initiated	Dougherty & Company	Buy
Nov-28-18	Initiated	Berenberg	Sell
Oct-29-18	Initiated	Leerink Partners	Outperform
May-29-18	Initiated	Guggenheim	Buy
May-29-18	Initiated	Stifel	Buy
May-29-18	Initiated	Wells Fargo	Outperform

Inspire Medical Systems Inc Stock (INSP) Financials Data

Period	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period End Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	911.98	802.80	624.80	407.86	233.39
Cost of revenue USD (M)	133.23	122.99	96.58	66.12	33.28
Gross profit USD (M)	778.76	679.82	528.22	341.74	200.12
Research and development USD (M)	103.17	114.13	116.54	68.65	37.35
Operating expenses USD (M)	-	-	568.49	389.33	239.97
Operating income USD (M)	50.95	36.08	-40.27	-47.59	-39.85
Income before tax USD (M)	65.70	58.45	-19.91	-44.27	-41.97
Income tax expense USD (M)	-79.73	4.94	1.25	0.61	0.07
Net income USD (M)	145.42	53.51	-21.15	-44.88	-42.04
Basic EPS USD/shares	4.95	1.80	-0.72	-1.60	-1.54
Diluted EPS USD/shares	4.89	1.75	-0.72	-1.60	-1.54
Basic weighted shares shares (M)	29.37	29.76	29.30	28.07	27.26
Diluted weighted shares shares (M)	29.76	30.54	29.30	28.07	27.26
Selling, general and administrative USD (M)	624.64	529.61	451.96	320.69	202.62

Inspire Medical Systems Inc Stock (INSP) Insider Trading

JOHN RONDONIAug 24 '26
Officer
Transaction
Proposed Sale
Cost
$62.36
#Shares
64
Value ($)
3,991
#Shares Total
0
JASON P KELLYAug 07 '26
Officer
Transaction
Proposed Sale
Cost
$59.55
#Shares
963
Value ($)
57,342
#Shares Total
0
Kelly Jason PAug 07 '26
See Remarks
Transaction
Sale
Cost
$59.55
#Shares
963
Value ($)
57,347
#Shares Total
18,985
Rondoni JohnMay 15 '26
See Remarks
Transaction
Sale
Cost
$43.28
#Shares
2,641
Value ($)
114,302
#Shares Total
27,165
JOHN RONDONIMay 15 '26
Officer
Transaction
Proposed Sale
Cost
$43.28
#Shares
2,641
Value ($)
114,304
#Shares Total
0
JOHN RONDONIMay 14 '26
Officer
Transaction
Proposed Sale
Cost
$43.01
#Shares
700
Value ($)
30,106
#Shares Total
0
Rondoni JohnMay 14 '26
See Remarks
Transaction
Sale
Cost
$43.01
#Shares
700
Value ($)
30,107
#Shares Total
29,806
SHAWN T MCCORMICKMay 08 '26
Director
Transaction
Proposed Sale
Cost
$45.57
#Shares
696
Value ($)
31,717
#Shares Total
0
mcCormick ShawnMay 08 '26
Director
Transaction
Sale
Cost
$45.31
#Shares
696
Value ($)
31,536
#Shares Total
27,712
Rondoni JohnJan 09 '26
See Remarks
Transaction
Sale
Cost
$100.00
#Shares
109
Value ($)
10,900
#Shares Total
13,797

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
JOHN RONDONI	Officer	Aug 24 '26	Proposed Sale	$62.36	64	3,991	0
JASON P KELLY	Officer	Aug 07 '26	Proposed Sale	$59.55	963	57,342	0
Kelly Jason P	See Remarks	Aug 07 '26	Sale	$59.55	963	57,347	18,985
Rondoni John	See Remarks	May 15 '26	Sale	$43.28	2,641	114,302	27,165
JOHN RONDONI	Officer	May 15 '26	Proposed Sale	$43.28	2,641	114,304	0
JOHN RONDONI	Officer	May 14 '26	Proposed Sale	$43.01	700	30,106	0
Rondoni John	See Remarks	May 14 '26	Sale	$43.01	700	30,107	29,806
SHAWN T MCCORMICK	Director	May 08 '26	Proposed Sale	$45.57	696	31,717	0
mcCormick Shawn	Director	May 08 '26	Sale	$45.31	696	31,536	27,712
Rondoni John	See Remarks	Jan 09 '26	Sale	$100.00	109	10,900	13,797

Inspire Medical Systems Inc Stock (INSP) Latest News

Nov 02, 2026

Inspire Medical Systems (INSP) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research

Nov 02, 2026

Here's What Key Metrics Tell Us About Inspire (INSP) Q3 Earnings - Zacks Investment Research

Nov 02, 2026

Oct 23, 2026

Inspire Medical Systems Inc. (US4577301090.SG) stock price, news, quote and history - Yahoo Finance UK

Oct 23, 2026